Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Receives Consensus Recommendation of "Moderate Buy" from Brokerages

Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Get Free Report) have received an average rating of "Moderate Buy" from the twenty-four research firms that are currently covering the company, MarketBeat reports. Five analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among analysts that have updated their coverage on the stock in the last year is $163.91.

NBIX has been the subject of a number of recent analyst reports. Jefferies Financial Group upped their target price on Neurocrine Biosciences from $177.00 to $189.00 and gave the company a "buy" rating in a report on Monday, August 19th. Royal Bank of Canada lowered their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating on the stock in a report on Friday, October 4th. Citigroup lifted their target price on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a research note on Friday, August 2nd. Cantor Fitzgerald restated an "overweight" rating and set a $155.00 price target on shares of Neurocrine Biosciences in a report on Monday, September 16th. Finally, StockNews.com upgraded Neurocrine Biosciences from a "buy" rating to a "strong-buy" rating in a report on Sunday, August 4th.

Neurocrine Biosciences Stock Up 1.6 %

Neurocrine Biosciences stock traded up $1.94 during midday trading on Friday, reaching $122.21. The stock had a trading volume of 1,512,407 shares, compared to its average volume of 863,768. Neurocrine Biosciences has a 12 month low of $103.63 and a 12 month high of $157.98. The firm's 50-day moving average price is $120.38 and its 200 day moving average price is $133.55. The firm has a market capitalization of $12.34 billion, a PE ratio of 32.59 and a beta of 0.36.

Neurocrine Biosciences (NASDAQ:NBIX - Get Free Report) last issued its quarterly earnings data on Wednesday, October 30th. The company reported $1.24 EPS for the quarter, missing the consensus estimate of $1.47 by ($0.23). The business had revenue of $622.10 million for the quarter, compared to analysts' expectations of $604.11 million. Neurocrine Biosciences had a return on equity of 15.68% and a net margin of 17.21%. Equities research analysts expect that Neurocrine Biosciences will post 4.37 EPS for the current year.

Insider Buying and Selling at Neurocrine Biosciences

In related news, Director Gary A. Lyons sold 11,570 shares of Neurocrine Biosciences stock in a transaction that occurred on Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total transaction of $1,740,475.10. Following the sale, the director now directly owns 119,047 shares in the company, valued at $17,908,240.21. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, Director Gary A. Lyons sold 11,570 shares of the stock in a transaction dated Tuesday, August 13th. The shares were sold at an average price of $150.43, for a total value of $1,740,475.10. Following the completion of the sale, the director now owns 119,047 shares in the company, valued at $17,908,240.21. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, Director William H. Rastetter sold 14,250 shares of the business's stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $146.69, for a total value of $2,090,332.50. Following the completion of the sale, the director now owns 37,491 shares in the company, valued at approximately $5,499,554.79. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 47,336 shares of company stock valued at $7,063,652 in the last ninety days. 4.30% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Assetmark Inc. lifted its holdings in shares of Neurocrine Biosciences by 10.6% during the 3rd quarter. Assetmark Inc. now owns 18,323 shares of the company's stock valued at $2,111,000 after buying an additional 1,753 shares during the period. Beacon Harbor Wealth Advisors Inc. purchased a new position in Neurocrine Biosciences in the third quarter worth about $5,521,000. Kornitzer Capital Management Inc. KS purchased a new position in Neurocrine Biosciences in the third quarter worth about $3,588,000. AlphaCentric Advisors LLC lifted its stake in Neurocrine Biosciences by 221.4% in the third quarter. AlphaCentric Advisors LLC now owns 22,500 shares of the company's stock worth $2,592,000 after purchasing an additional 15,500 shares during the last quarter. Finally, Impax Asset Management Group plc raised its stake in shares of Neurocrine Biosciences by 70.0% during the third quarter. Impax Asset Management Group plc now owns 85,000 shares of the company's stock valued at $9,794,000 after acquiring an additional 35,000 shares in the last quarter. Institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.